Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review

奥西默替尼 医学 吉非替尼 T790米 肺癌 间质性肺病 阿法替尼 培美曲塞 肿瘤科 腺癌 内科学 人口 表皮生长因子受体 化疗 病理 埃罗替尼 癌症 顺铂 环境卫生
作者
Longqiu Wu,Wu Zhong,Li An,Zhengang Qiu,Rongrong Xie,Huaqiu Shi,Shun Lu
出处
期刊:Annals of Translational Medicine [AME Publishing Company]
卷期号:9 (11): 950-950 被引量:7
标识
DOI:10.21037/atm-21-2823
摘要

: Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have revolutionized the standard treatment for EGFR T790M-positive non-small cell lung cancer (NSCLC). Osimertinib is one of the third-generation EGFR-TKIs and is currently the most advanced in clinical development. Interstitial lung disease (ILD) is a potentially fatal side effect of osimertinib use. Successful rechallenge with the second-generation TKI afatinib following osimertinib-induced ILD has been reported. However, few reports have discussed the safety and efficacy of third-generation TKI rechallenge in this patient population. In this paper, a case of lung adenocarcinoma is retrospectively analyzed, and the relevant literature is reviewed. The patient was initially diagnosed with early lung cancer, for which surgical treatment was performed. The postoperative diagnosis indicated stage IB (pT2N0M0) right lung adenocarcinoma. Genetic testing (amplification-refractory mutation system) revealed EGFR exon 19 deletion. More than 2 years after surgery, multiple metastases occurred in both lungs, so gefitinib (250 mg per day) was administered. However, 6 months after the start of gefitinib treatment, the tumor progressed. Lung tumor biopsy was performed for genetic testing (NGS) and an EGFR T790M mutation was observed. Subsequently, second-line treatment with osimertinib (80 mg per day) was given for 3 months. The evaluated response suggested a partial response (PR) with the occurrence of grade 3 ILD. Pemetrexed plus bevacizumab chemotherapy was subsequently administered, resulting in stable disease. However, following a severe drug reaction after six courses, the patient’s chemotherapy was discontinued. Another third-generation TKI, almonertinib (110 mg per day), was rechallenged based on no ILD having been reported in a phase I/II study of this drug. After 4 months of almonertinib administration and 6 months without ILD recurrence, partial remission was attained. This is the first report of successful treatment with almonertinib after osimertinib-induced ILD. The results suggested that almonertinib had a significant effect in patients with EGFR T790M mutation, with fewer side effects and better survival benefits for patients with advanced lung cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JamesPei应助加特林采纳,获得10
刚刚
2秒前
4秒前
flysky120发布了新的文献求助10
4秒前
5秒前
downloadpapers应助冯宝宝采纳,获得10
5秒前
乐乐应助Alice采纳,获得30
6秒前
6秒前
whyzz完成签到,获得积分10
7秒前
希望天下0贩的0应助yanning采纳,获得10
8秒前
8秒前
加特林发布了新的文献求助10
9秒前
yang发布了新的文献求助10
10秒前
orixero应助雨淋沐风采纳,获得10
10秒前
共享精神应助忧郁凌波采纳,获得10
16秒前
18秒前
Jasper应助Zn0103采纳,获得10
19秒前
桐桐应助皛鑫森淼焱垚采纳,获得10
21秒前
吟賞烟霞发布了新的文献求助10
21秒前
yang完成签到,获得积分10
22秒前
李爽完成签到,获得积分10
24秒前
kk完成签到 ,获得积分10
24秒前
25秒前
13863355284完成签到,获得积分10
26秒前
26秒前
李亨达完成签到,获得积分20
27秒前
机智的白猫完成签到 ,获得积分10
29秒前
30秒前
kevinjy完成签到,获得积分10
30秒前
31秒前
忧郁凌波发布了新的文献求助10
31秒前
31秒前
烟花应助丁真先生采纳,获得10
31秒前
封尘逸动发布了新的文献求助10
32秒前
33秒前
小席发布了新的文献求助10
33秒前
张楚懿完成签到,获得积分10
34秒前
07发布了新的文献求助10
34秒前
35秒前
36秒前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Effect of reactor temperature on FCC yield 2000
Very-high-order BVD Schemes Using β-variable THINC Method 1020
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Mission to Mao: Us Intelligence and the Chinese Communists in World War II 600
The Conscience of the Party: Hu Yaobang, China’s Communist Reformer 600
Geochemistry, 2nd Edition 地球化学经典教科书第二版,不要epub版本 431
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3302000
求助须知:如何正确求助?哪些是违规求助? 2936557
关于积分的说明 8478065
捐赠科研通 2610335
什么是DOI,文献DOI怎么找? 1425076
科研通“疑难数据库(出版商)”最低求助积分说明 662289
邀请新用户注册赠送积分活动 646456